It was the topic that set ASCO on its ear: current trials now indicate that adding trastuzumab prolongs disease-free survival. The data are so strong, they warrant a change in the standard of care from adjuvant anthracycline therapy, with or without taxanes, to adjuvant treatment with trastuzumab for eligible patients with HER2+ resected breast cancer.
|Original language||English (US)|
|State||Published - Jan 1 2005|
ASJC Scopus subject areas